http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Epizyme Announces Presentations at 57th American Society of Hematology Annual Meeting
-
Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
-
Epizyme to Report Third Quarter 2015 Financial Results and Provide Corporate Update on November 9, 2015
-
Epizyme Announces Updated Tazemetostat Phase 1 Data Showing Clinical Activity in a Broader Range of Adults With INI1-Negative and SMARCA4-Negative Solid Tumors
-
Epizyme, Inc. to Present at Upcoming Events in September
-
Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma
-
Epizyme Announces Second Quarter 2015 Financial Results and Provides Corporate Update
-
Epizyme Appoints Robert Bazemore President and Chief Executive Officer
-
Epizyme, Inc. to Present at 2015 Wedbush PacGrow Healthcare Conference
-
Epizyme to Report Second Quarter 2015 Financial Results and Provide Corporate Update on August 6, 2015
-
Epizyme Doses First Patient in Five-Arm Phase 2 Study for First-in-Class EZH2 Inhibitor Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma
-
Epizyme Announces Extension of Celgene Research Collaboration
-
Epizyme to Present Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat (EPZ-6438) at the European Cancer Congress
-
Market Wrap: Existing Home Sales Outpace in May; Twitter Details CEO Search; Merger Monday
-
Epizyme Announces Additional Positive Data from Ongoing Phase 1 Study of Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma
-
Epizyme, Inc. to Present at Upcoming Events in June
-
Epizyme to Present at Upcoming Conferences in May
-
Epizyme Announces First Quarter 2015 Financial Results and Provides Corporate Update
-
Trading Radar for 4/28: Ford (F), Aetna (AET), Twitter (TWTR), GoPro (GPRO), Panera Bread (PNRA) Report
-
Epizyme to Report First Quarter 2015 Financial Results and Provide Corporate Update on April 28, 2015
-
Epizyme Presents Preclinical Research Providing Deeper Understanding of Multiple Cancer Targets
-
Epizyme to Present Updated Data from Ongoing Phase 1 Dose Escalation Trial of EZH2 Inhibitor EPZ-6438 at International Conference on Malignant Lymphoma
-
Epizyme to Present Data on Preclinical Pipeline at the American Association for Cancer Research (AACR) Annual Meeting
-
Epizyme Reacquires Global Rights from Eisai for First-in-Class EZH2 Inhibitor EPZ-6438
-
Epizyme Announces 2014 Financial Results and Provides Corporate Update
-
Epizyme to Report Fourth Quarter 2014 Financial Results and Provide Corporate Update on March 12, 2015

